Navigation Links
Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Date:2/7/2008

BOSTON and CARLSBAD, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented demonstrating the potent activity of the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds against the human-immunodeficiency virus (HIV), the known causative agent of AIDS, including NNRTI-resistant strains.

The data was presented at the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The data showed that Ardea's lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieves trough levels in humans that average at least 10-fold higher than the serum-adjusted EC50.

"This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral therapy," said Barry D. Quart, PharmD, Ardea's President and CEO. "NNRTIs are a critical component of current HIV therapy; however, there is an unmet need for safer, better tolerated NNRTIs that also work against viruses resistant to the most widely used NNRTIs."

The posters are available on the conference website (http://www.retroconference.org) and on the Company website (http://www.ardeabio.com) under the titles "An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins" and "RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity against NNRTI-Re
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ober 7 /-,Sosei Group Corpo...ura,Group plc ("Vectura"; LSE: VEC), announce resu...y, safety and tolerability of NVA237 presented at ...ciety (ERS) in Berlin,Germany. The new data show ...led long-acting muscarinic antagonist (LAMA), prov...
(Date:10/6/2008)... the understanding of and possible treatm...LLERICA, Mass., Oct. 6 /- Seahorse Bi...ever analytical instrument for the,kinetic measure...lasmic,glycolysis in cells in a 96 well microplate...ar bioenergetics have been relatively unchanged si...
(Date:10/6/2008)...t The American College of Nutrition .../- New research on the benefits of,pr...The American College of,Nutrition (ACN) Annual Mee...obiotics in Health and Disease." Scientific expert...n discussed the potential uses for,probiotics in c...
(Date:10/6/2008)... Oct. 6 /- Complete,Genomics Inc., a ...encing,company, and the Institute for Systems Biol...duct populationwide human genome studies., In pha...its proprietary,DNA sequencing technology to seque...n, once proof-of-concept has been demonstrated, IS...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Climate change could impact vital functions of microbes 20921 1Climate change could impact vital functions of microbes 20921 2Climate change could impact vital functions of microbes 20921 3Natural Solutions Names 45 Must Have Foods for Healthy Weight Loss 20916 1Natural Solutions Names 45 Must Have Foods for Healthy Weight Loss 20916 2Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference 5756 1Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference 5756 2EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 1EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 2EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 3EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 4
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...t even older patients benefit from timely treatmen...ttack), a researcher //has warned in the latest is...ating people over 80 in a timely manner. In other ...geism is rampant in health services. Professor Jo...
...s are linked to allergic reaction in a manner with... are released. However, researchers at Karolinska/...e diseases like psoriasis and cancer. Mast cells...p with allergic reactions, as they behave similar ...
...tenance of strong bones, strong and healthy teeth,...al, calcium.// It is vital to take plenty of cal...ect bones later in life and to prevent osteoporosi...es place till the age of 30-35. Bone mass can be b...
...searchers from the University of Kentucky being cl...preventing blood clots during procedures so// as t...ccording to Dr. Steven Steinhubl, the co-chairman ... to appear in the latest issue of the New England ...
Other Medicine News:Health News:Cancer and psoriasis triggered by mast cells 2Health News:Enoxaparin To Become The Standard Treatment During Procedures For Blocked Arteries 2
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills.
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs
23 cm - 9, adult size, for skull thickness up to 12 mm.
Length-9 (229 mm) Tapered retractor blades.
Medicine Products: